Form 8-K · Current Report · Filed 2024-06-25
Biogen Inc. Adopts Exculpation Provision and Elects New Board Members
On June 20, 2024, Biogen Inc. held its Annual Meeting of Stockholders where several key decisions were made. Stockholders approved and adopted a Certificate of Amendment to the company's Amended and Restated Certificate of Incorporation, which allows for exculpation of certain officers to the extent permitted by Delaware law. Additionally, stockholders elected nine new members to the Board of Directors, ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm, approved the advisory vote on executive compensation, approved an amendment to the company's certificate of incorporation to add an officer exculpation provision, and approved the adoption of the Biogen Inc. 2024 Omnibus Equity Plan and the Biogen Inc. 2024 Employee Stock Purchase Plan.
- Filer
- Biogen Inc. BIIB · NASDAQ
- Filed
- Accession
- 0001193125-24-167938
- CIK
- 0000875045
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Amendments to Articles of Incorporation or Bylaws
Submission of Matters to a Vote of Security Holders
Financial Statements and Exhibits
Market reaction
Close before filing
$226.60
Next session
-0.9%
Since filing
-10.4%
Latest close
$202.95
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BIIB reporting the same item, with the next session's move:
Exhibits (1)
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Never miss another BIIB filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.